Related Experiment Video

Updated: Dec 15, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer

Z Chen1,2, Y Li3, B Tan4

  • 1Graduate School of Hebei Medical University, Shijiazhuang, China.

Drugs of Today (Barcelona, Spain : 1998)
|July 11, 2020
PubMed

Insights

Targeted therapy offers survival benefits for advanced gastric cancer patients, but drug resistance remains a significant challenge. This review explores the complex mechanisms driving resistance and discusses future directions for overcoming it.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastric cancer is a leading cause of cancer mortality globally, particularly in China.
  • Targeted therapies, including those against EGFR, HER2, VEGF, mTOR, and CLDN 18.2, improve outcomes for advanced gastric cancer.
  • Drug resistance is a major obstacle in the efficacy of targeted therapies for gastric cancer.

Purpose of the Study:

  • To review the mechanisms of drug resistance in gastric cancer targeted therapy.
  • To summarize the current research status of drug resistance in molecular targeted therapy for gastric cancer.
  • To highlight the clinical significance of understanding and overcoming targeted drug resistance.

Main Methods:

  • Literature review of mechanisms of drug resistance in gastric cancer targeted therapy.
  • Summary of current research on drug resistance in molecular targeted therapy.
  • Exploration of future prospects for targeted therapy in gastric cancer.

Main Results:

  • Key resistance mechanisms include compensatory signaling pathways, target protein alterations, tumor microenvironment changes, heterogeneity, and drug adaptation.
  • The interplay of multiple resistance mechanisms accelerates the development of targeted drug resistance.
  • Understanding these mechanisms is crucial for developing strategies to reverse resistance.

Conclusions:

  • Overcoming drug resistance is critical for improving long-term patient survival in gastric cancer.
  • Further research into resistance mechanisms and novel therapeutic strategies is warranted.
  • Future developments in molecular targeted therapy hold promise for overcoming resistance and enhancing treatment efficacy.
Keywords:
ChemotherapyDrug resistanceGastric cancerMolecule-targeted therapyMonoclonal antibodiesSmall-molecule drugsTargeted drugs

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K